All In Biotech

Drug Trial Radar · NCT05204862

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

A Phase 1/2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Inhibitor, Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Dec 2, 2021

Primary completion

Jun 30, 2026

Study completion Sep 30, 2027

Sponsor

Lead sponsor
TiumBio Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors. The main purpose of Phase 1 is to determined the recommended Phase 2 dose (RP2D) of TU2218 and the main purpose of Phase 2 is to evaluate the antitumor activity of TU2218 at RP2D.

Conditions

  • Advanced Solid Tumor

Interventions

  • TU2218Drug

    orally administered

  • Anti-PD-1 antibodyDrug

    Intravenously administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Maximum Tolerated Dose (MTD) of TU2218 administered alone (Part A) and in combination with anti-PD-1 antibody (Part B)Time frame: From the beginning of Cycle 1 through Cycle 2 (each cycle is 21 days)
  2. Phase 2: Overall Response rate (ORR) of TU2218 administered alone (Part A) and in combination with anti-PD-1 antibody (Part B)Time frame: 24 weeks

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.